Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTrellus Health. Regulatory News (TRLS)

Share Price Information for Trellus Health. (TRLS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.94
Bid: 1.50
Ask: 2.00
Change: 0.00 (0.00%)
Spread: 0.50 (33.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.94
TRLS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trellus IBD program launches on GI OnDEMAND

19 Oct 2022 07:00

RNS Number : 3299D
Trellus Health PLC
19 October 2022
 

 

Trellus Health plc

("Trellus Health" or the "Company")

 

Trellus IBD program launches on GI OnDEMAND

 

Partnership with leading GI virtual integrated care platform enables US gastroenterology practices to deliver coordinated and personalized behavioral and nutritional support for IBD Patients

 

LONDON, U.K. AND NEW YORK, U.S. (19 October 2022): Trellus Health plc (AIM: TRLS), which is commercializing a scientifically validated, personalized resilience-driven self-management solution for chronic health conditions at their intersection with mental health, announces that the Trellus Resilience Training and Self-Management Solution for Inflammatory Bowel Disease (the "Trellus IBD program") is now available on GI OnDemand, gastroenterology's leading multidisciplinary virtual integrated care platform.

 

GI OnDEMAND, a joint venture between the American College of Gastroenterology ("ACG") and Gastro Girl, Inc., now offers the Trellus IBD program, to all GI OnDEMAND and ACG members nationwide to coordinate and deliver personalized behavioral, emotional and nutritional support for their IBD patients remotely via digital solutions, and access to an expert resilience team via telehealth. The Trellus IBD program will be the only resilience driven self-management training solution offered via this platform to over 16,000 gastrointestinal ("GI") professionals across the US for the benefit of the millions of patients they collectively serve.

 

ACG champions the prevention, diagnosis, and treatment of digestive disorders, serving to guide the delivery of the highest quality, compassionate and evidence-based patient care. It seeks to enhance the ability of its members to provide world class care to patients with digestive disorders and advance the profession through excellence and innovation.

 

The partnership with GI OnDEMAND forms a key part of Trellus Health's strategy to expand access to its self-management solution through multiple channels, including via healthcare providers and directly to patients, and is expected to prove to be a key channel to market for accessing D2C customers. Trellus Health intends to leverage the data generated on expected improvements in outcomes and on reductions in the cost of caring for GI patients, to support the wider rollout of its solution to both private and nationally funded healthcare payers.

 

Jacqueline Gaulin, Founder, Chief Strategy Officer, Gastro Girl/GI OnDEMAND said: "Our partnership with Trellus Health reflects a mutual passion for taking a multidisciplinary approach to patient care and an unwavering mission to make digestive health expertise, resources and support accessible to everyone. We look forward to working together with the Trellus team to further expand the awareness and reach of the Trellus IBD program so all patients with IBD have access to this personalized and evidence-based program that gives them the tools and the team to better manage their health and live well physically, emotionally and socially."

 

William Chey, MD, FACG, Chief, Division of Gastroenterology & Hepatology, Michigan Medicine and Senior Director, Nutrition and Behavioral Health Services, GI OnDEMAND, said: "GI OnDEMAND expands a provider's ability to deliver a first-in-class patient self-management solution for IBD. All of our members' patients can now have access to a digitally delivered, resilience based, self-management training program developed and validated at Mount Sinai (NY) to enable them to take charge of their health needs, access behavioral and emotional support in between office visits, and to experience better outcomes. This is exactly what our GI patients need."

 

Dr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said: "I am delighted to launch our partnership with GI OnDemand which adds another significant growth channel under our D2C model to support the commercialization of the Trellus IBD Self-management Program. We will be the only resilience training solution offered to this network of over 16,000 US based GI professionals and alongside our licensing agreement with the Crohn's and Colitis Foundation, the largest patient advocacy group for IBD in the US, we have already established the broadest possible reach into the US gastroenterological community, to access both patients and GI providers nationwide."

 

About the Trellus IBD program

Trellus Health is pioneering a scientifically validated, personalized resilience-driven self-management solution for chronic health conditions which addresses the intersection of chronic illness with mental health, estimated to cost the US economy $3.7 trillion annually.1 The Trellus approach transforms chronic condition management and changes the lives of patients living with debilitating, incurable conditions, initially focused on IBD, including Crohn's Disease and ulcerative colitis, and shortly IBS, but with potential utility and demand across many chronic conditions.

 

The Trellus IBD program is a self-management solution driven by personalized resilience training. The program empowers and enables members to manage their condition by teaching them to set goals, actively identify challenges and solve problems associated with their condition, driving a change of health behavior to deliver improved outcomes and health status at lower cost.

 

Patients with IBD face many challenges which are common across many chronic conditions: the management of complex medication regimens, dealing with symptoms and disability, monitoring physical indicators, maintaining proper levels of nutrition, adjusting to the psychological and social demands including difficult lifestyle adjustments, as well as engaging in effective interactions with health providers.

 

Trellus's personalized resilience-driven self-management training programs are designed specifically for people looking to overcome these challenges. The aim is to provide better quality patient outcomes at a lower cost to health plans and employers, and the proprietary resilience method has been proven to reduce unplanned hospitalizations by 94% at the Mount Sinai IBD Center, New York, NY.2

 

For further information please contact:

 

Trellus Health plc

www.trellushealth.com

Julian Baines, Chairman

Via Walbrook PR

Singer Capital Markets (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / Jen Boorer

Walbrook PR Limited

Tel: 020 7933 8780 or trellus@walbrookpr.com

Paul McManus / Sam Allen / Phillip Marriage

Mob: 07980 541 893 / 07748 651 727 / 07867 984 082

 

 

About Trellus Health plc (www.trellushealth.com)

Trellus Health (LSE: TRLS) is the first resilience based digital health company focused on the intersection of chronic illness and mental health. Trellus Health integrates its proprietary resilience-based methodology with the technology, tools and team to deliver a whole-person technology-enhanced experience that results in relieving disease burden, building self-management skills and promoting individual health behaviors that enable thriving in the face of a chronic condition. Through its TrellusElevate™ connected health platform and companion App, the company addresses both physical and behavioral health together, in context, to improve outcomes and reduce healthcare costs across the healthcare ecosystem.

 

The Company is initially focused on Inflammatory bowel disease ("IBD"), which includes the chronic incurable conditions of Crohn's Disease and ulcerative colitis, and shortly Irritable Bowel Syndrome ("IBS"), but, given the common struggles of self-management, considers its approach to have potential utility and demand across many chronic conditions.

 

The TrellusElevate™ platform is the Company's proprietary connected health platform that incorporates the GRITT™ methodology and learnings on resilience from clinical research and practice conducted at the Mount Sinai IBD Center for more than five years. This proprietary, resilience-driven methodology has been scientifically validated to demonstrate meaningful improvements in patient outcomes, 71% reduction in Emergency Department (A&E) visits, and 94% reduction in unplanned hospitalisations, which the directors of the Company believe indicates the potential for significant cost savings for healthcare payers. Patients with IBD treated using the methodology also experienced a 49% reduction in required opioid use and a 73% reduction in corticosteroid use 12 months following starting the program2.

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both with decades of combined experience in IBD and psychogastroenterology, respectively. Trellus Health's patent-pending GRITT™ resilience assessment and personalized resilience training methodology was developed and validated at the Mount Sinai Health System to build resilience and wellness for improved outcomes at lower cost.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information on Trellus Health, visit:  www.trellushealth.com

 

1) Source: https://www.cdc.gov/chronicdisease/about/costs/index.htm)

2) Source: https://www.sciencedirect.com/science/article/pii/S1542356521012258).

 

About GI OnDEMAND®

GI OnDEMAND is a joint venture between the American College of Gastroenterology (ACG) and Gastro Girl, Inc. As gastroenterology's leading multidisciplinary virtual care platform, GI OnDEMAND brings the full-ecosystem of GI experts, resources and support together for GI clinicians and patients. GI OnDEMAND makes it easier for GI practices to adopt a virtual integrated care model and amplify the expertise and value the practice brings to patients with access to vetted GI expert registered dietitians, GI psychologists, as well as genetic testing and expert genetic counselling. GI OnDEMAND also features telehealth capabilities, access to evidence-based educational programs.

 

About the American College of Gastroenterology Founded in 1932, the American College of Gastroenterology (ACG) is an organization with an international membership of over 17,000 individuals from 86 countries. The College's vision is to be the preeminent professional organization that champions the prevention, diagnosis, and treatment of digestive disorders, serving as a beacon to guide the delivery of the highest quality, compassionate, and evidence-based patient care. The mission of the College is to enhance the ability of our members to provide world class care to patients with digestive disorders and advance the profession through excellence and innovation based upon the pillars of Patient Care, Education, Scientific Investigation, Advocacy and Practice Management. www.gi.org

 

About Gastro Girl

Gastro Girl, Inc., is a patient-centric health company that empowers individuals to achieve optimal digestive health. Since 2016 Gastro Girl has served as the official patient education partner of The American College of Gastroenterology (ACG). Gastro Girl and ACG expanded this partnership in 2019 to make digestive health expertise, resources and support available to everyone via GI OnDEMAND. In addition to connecting patients to GI experts- including gastroenterologists, registered dietitians, and psychologists via GI OnDEMAND, Gastro Girl delivers actionable and evidence-based health information and resources to help everyone achieve better health, including the Gastro Girl Podcast gastrogirl.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUWRRRUVURAUA
12
Date   Source Headline
30th Apr 202411:29 amRNSHolding(s) in Company
23rd Apr 20247:00 amRNSPreliminary Results
17th Apr 20244:16 pmRNSHolding(s) in Company
16th Apr 20245:02 pmRNSHolding(s) in Company
16th Apr 20247:00 amRNSNotice of Results
2nd Apr 20244:36 pmRNSHolding(s) in Company
5th Mar 20247:00 amRNSGrant of Share Options
28th Feb 202412:00 pmRNSDirectorate Change
28th Feb 20247:00 amRNSAgreement with US Health Plan
28th Sep 20237:00 amRNSHalf-year Report
14th Sep 20237:00 amRNSNotice of Results
12th Sep 20237:00 amRNSAppointment of Chief Financial Officer
22nd Jun 20231:37 pmRNSResult of AGM
13th Jun 20237:00 amRNSRelated Party Transactions
26th May 20237:00 amRNSPosting of Annual Report and Notice of AGM
23rd May 20237:00 amRNSFinal Results
28th Apr 20237:00 amRNSNotice of Results
6th Mar 20237:00 amRNSTrading Update
17th Feb 20237:00 amRNSLaunch of D2C IBS Offering
13th Feb 20237:00 amRNSNew York Medicaid Health Plan Agreement
6th Feb 20237:01 amRNSDirectorate Change
20th Dec 20227:00 amRNSTrading Update & Related Party Transaction
14th Dec 20225:28 pmRNSHolding(s) in Company
19th Oct 20227:00 amRNSTrellus IBD program launches on GI OnDEMAND
17th Oct 20227:00 amRNSTwo contracts signed with Mount Sinai
5th Oct 20229:06 amRNSSecond Price Monitoring Extn
5th Oct 20229:00 amRNSPrice Monitoring Extension
30th Sep 20224:41 pmRNSSecond Price Monitoring Extn
30th Sep 20224:35 pmRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSHalf-year Report
26th Sep 20227:00 amRNSMarla Dubinsky a recipient of 2022 Sherman Prize
22nd Sep 20227:00 amRNSNotice of Results and Investor Presentation
1st Aug 20227:00 amRNSAppointment of Chief Financial Officer
19th Jul 20227:00 amRNSDirectorate Changes
27th Jun 20222:47 pmRNSResult of AGM and voting results
23rd Jun 20227:00 amRNSDirectorate Change
25th May 202212:00 pmRNSPosting of Annual Report & Accounts
10th May 20227:01 amRNSInvestor Presentation
10th May 20227:00 amRNSFinal Results
7th Apr 20227:00 amRNSNotice of Results
28th Feb 20227:00 amRNSDirect to Consumer market launch in New York
21st Jan 20227:00 amRNSAppointment of Chief Financial Officer
17th Jan 20227:00 amRNSClinical research update on GRITT(tm) methodology
4th Jan 20227:00 amRNSDirectorate Change
20th Dec 20213:44 pmRNSIssue of Equity
14th Dec 20217:00 amRNSTrading update
22nd Sep 20217:00 amRNSHalf-year Report
16th Sep 20217:00 amRNSNew Partnership Agreement & Licensed Clinical Team
9th Sep 20217:00 amRNSNotice of Results
23rd Aug 20217:00 amRNSFirst Demonstration Programme Contract
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.